- Home
- CNTX
as 10-24-2025 3:55pm EST
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 75.6M | IPO Year: | 2021 |
| Target Price: | $5.20 | AVG Volume (30 days): | 500.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.49 - $2.46 | Next Earning Date: | 11-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Context Therapeutics Inc. News
CNTX Breaking Stock News: Dive into CNTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
19 days ago
Institutions profited after Context Therapeutics Inc.'s (NASDAQ:CNTX) market cap rose US$14m last week but private equity firms profited the most
GlobeNewswire
21 days ago
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
GlobeNewswire
23 days ago
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
24 days ago
Cantor Fitzgerald Initiates Context Therapeutics at Overweight
Simply Wall St.
4 months ago
Co-Founder of Context Therapeutics Martin Lehr Buys 10% More Shares
GlobeNewswire
5 months ago
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
GlobeNewswire
5 months ago
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
GlobeNewswire
5 months ago
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare CNTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CNTX Context Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.